Otsuka (OTCMKTS:OTSKY) Reaches New 52-Week High – Here’s What Happened

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) shares reached a new 52-week high during trading on Wednesday . The stock traded as high as $35.1699 and last traded at $33.92, with a volume of 25855 shares. The stock had previously closed at $31.66.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on OTSKY shares. The Goldman Sachs Group cut Otsuka from a “strong-buy” rating to a “strong sell” rating in a research note on Friday, February 27th. Zacks Research lowered shares of Otsuka from a “hold” rating to a “strong sell” rating in a research note on Monday, March 2nd. Morgan Stanley upgraded shares of Otsuka to an “overweight” rating in a research report on Friday, January 23rd. Finally, UBS Group upgraded shares of Otsuka to a “hold” rating in a report on Tuesday, January 27th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Otsuka has an average rating of “Reduce”.

Otsuka Price Performance

The company has a fifty day moving average price of $30.86 and a two-hundred day moving average price of $28.88.

About Otsuka

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.